We investigated the expression of ␣ 1 -adrenergic receptor subtypes in intact human peripheral blood lymphocytes using reverse transcription-polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of ␣ 1 -adrenergic receptors (␣ 1A , ␣ 1B , and ␣ 1D ). RT-PCR amplified in peripheral blood lymphocytes a 348-bp ␣ 1A -adrenergic receptor fragment, a 689-bp ␣ 1B -adrenergic receptor fragment, and a 540-bp ␣ 1D -adrenergic receptor fragment. Radioligand binding assay with [ 3 H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0.65Ϯ0.05 nmol/L and a maximum density of binding sites of 175.3Ϯ20.5 fmol/10 6 cells. The pharmacological profile of [ 3 H]prazosin binding to human peripheral blood lymphocytes was consistent with the labeling of ␣ 1 -adrenergic receptors. Antibodies against ␣ 1A -, ␣ 1B -, and ␣ 1D -receptor subtypes decreased [ 3 H]prazosin binding to a different extent. This indicates that human peripheral blood lymphocytes express the three ␣ 1 -adrenergic receptor subtypes. Of the three different ␣ 1 -adrenergic receptor subtypes, the ␣ 1B is the most represented and the ␣ 1D , the least. Future studies should clarify the functional relevance of ␣ 1 -adrenergic receptors expressed by peripheral blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of ␣ 1 -adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors. (Hypertension. 1999;33:708-712.) 
I n the past few years, ␣and ␤-adrenergic receptors have been demonstrated in peripheral blood lymphocytes with the use of radioligand binding assay techniques. The majority of information is available on ␤-adrenergic receptors, which were investigated primarily in essential hypertension, impaired left ventricular function, and acute stress. [1] [2] [3] [4] [5] Data on the expression of ␣-adrenergic receptors in peripheral blood lymphocytes are less extensive, with the ␣ 2 -receptor subtype being the most extensively investigated. 6, 7 Some studies on the ␣ 1 -adrenergic receptor have not found its expression in human peripheral blood lymphocytes 8, 9 and some studies have. 10 ␣ 1 -Adrenergic receptors mediate some cardiovascular sympathetic responses, such as arteriolar smooth muscle constriction 11 and cardiac contractility, 12 and are involved in a variety of cardiovascular disorders, including hypertension, heart failure, and cardiac hypertrophy. 13 ␣ 1 -Adrenergic receptors represent a class of heterogeneous receptors. 14 Cloning studies have identified three distinct ␣ 1 -adrenergic receptor subtypes, named ␣ 1a -, ␣ 1b -, and ␣ 1d -adrenergic receptors. 14 -17 At present, ␣ 1 -adrenergic receptor subtypes are defined as ␣ 1A (␣ 1a ), ␣ 1B (␣ 1b ), and ␣ 1D (␣ 1d ), with uppercase and lowercase subscripts being used to designate native or recombinant receptor, respectively. 14, 18 In view of the difficulty of investigating ␣ 1 -adrenergic receptors in vivo or in vitro using human samples of cardiovascular system, circulating blood cells may represent a model for the study of the cardiovascular ␣ 1 -adrenergic receptor system.
In this article we have characterized ␣ 1 -adrenergic receptor subtypes expressed by human peripheral blood lymphocytes by reverse transcription-polymerase chain reaction (RT-PCR) to detect mRNA expression and by radioligand binding assay techniques combined with antibodies against different subtypes of ␣ 1 -adrenergic receptors.
Methods

Subjects and Peripheral Blood Lymphocyte Separation
Blood samples (40 mL) were drawn from 30 healthy subjects (15 men and 15 women; age, 26 to 48 years), after informed consent had been obtained, for peripheral blood lymphocyte isolation. Cells were diluted 1:3 with phosphate-buffered saline (0.85% NaCl and 6.7 mmol/L potassium phosphate, pH 7.2) and separated on a Ficoll-Hypaque gradient. The layer of mononuclear cells was re-moved and resuspended. Cells (10ϫ10 6 ) were sedimented by centrifugation in Eppendorf tubes, lysed with 1 mL RNAfast by repetitive pipetting, and then stored at Ϫ80°C until further analysis. Cells used for radioligand binding assay after separation were collected in polypropylene tubes and immediately frozen at Ϫ80°C.
Reverse Transcription-Polymerase Chain Reaction
Total RNA was extracted using the RNAfast method. RT was performed using 1 g total RNA, according to the manufacturer's instructions (Perkin-Elmer). PCR was carried out in an automated DNA thermal cycler (Perkin-Elmer) using the following specific primers: ␣ 1A sense and antisense, 5Ј-ACTACATCGTCAACCTGGCG-3Ј and 5Ј-TGATCTGGCAGATGGTCTCG-3Ј, respectively; ␣ 1B sense and antisense, 5Ј-TCGGTGGCCTGCAACCGGCACCTG-3Ј and 5Ј-ATGCCCAAGGTTTTGGCTGCTTTCTT-3Ј, respectively; ␣ 1D sense and antisense, 5Ј-GTGGTGAGTGCTCAGGGCGTG-3Ј and 5Ј-GATGACCGCCATGGGCAGGT-3Ј. The amplification protocol was 90 seconds at 94°C, 2 minutes at 60°C, and 2 minutes at 72°C, with extension of 1 second per cycle for 30 cycles. PCR products were electrophoresed on a 1.5% agarose gel containing 0.5 mg/mL ethidium bromide. After gel electrophoresis, the amplified fragments of ␣ 1adrenergic receptor subtypes were blotted to nylon filters and hybridized with a specific nested oligonucleotide for each subtype of ␣ 1 -adrenergic receptor, and were labeled by T4 kinase with [␥-32 P]-ATP. Specific nested oligonucleotides used for ␣ 1A , ␣ 1B , and ␣ 1D were 5Ј-AACCATCGTCACCCAGAGGA-3Ј, 5Ј-ATGGAACTCCTGGGGT-TGTG-3Ј, and 5Ј-CTTATGGCCGTGGCAGGTAA-3Ј, respectively. A specific activity of 4ϫ10 6 cpm/mL was added to the hybridizing solution (5ϫ SSPE, 0.5ϫ SDS, 5ϫ Denhardt's solution), and the filters were incubated for 2 hours at 42°C. Filters were then washed twice in 2ϫ SSPE at room temperature and once in 5ϫ SSPE at 52°C and exposed for 24 to 48 hours at -80°C.
Radioligand Binding Assay
Three hundred microliters of a lymphocyte suspension containing 1ϫ10 6 cells was incubated in triplicate for 60 minutes at 25°C with increasing concentrations of [ 3 H]prazosin (0.05 to 4 nmol/L) in 50 mmol/L Tris-HCl containing 150 nmol/L NaCl, 5 mmol/L EDTA, 100 mol/L pargyline, and 3 mol/L ascorbic acid (pH 7.4). Nonspecific binding was defined by incubating lymphocytes with [ 3 H]prazosin in the presence of 10 mol/L phentolamine.
The pharmacological specificity of [ 3 H]prazosin binding to human peripheral blood lymphocytes was assessed by incubating suspensions containing 1ϫ10 6 cells with 0.5 nmol/L [ 3 H]prazosin in the presence of increasing concentrations (0.001 nmol/L to 1 mmol/L) of compounds active on adrenergic receptors, dopamine, and serotonin receptors.
At the end of incubation, cells were isolated onto Whatman GF-B glass fiber filters with the use of a manifold filtration apparatus. Filters were washed rapidly twice with ice-cold incubation buffer and transferred into scintillation vials for radioactivity measurement.
Experiments With Antibodies Against ␣ 1 -Adrenergic Receptor Subtypes
Suspensions of peripheral blood lymphocytes (1ϫ10 6 cells/mL) were preincubated for 1 to 2 hours at 25°C with increasing concentrations (0.05 to 2 g/mL) of goat polyclonal immunoglobulins raised against ␣ 1A -, ␣ 1B -, and ␣ 1D -adrenergic receptors. Immunoglobulins were used alone, in association (anti-␣ 1A and anti-␣ 1B , anti-␣ 1A and anti-␣ 1D , anti-␣ 1B and anti-␣ 1D ), and all together. For control purposes, peripheral blood lymphocytes were incubated with immunoglobulins preadsorbed with 10 g/mL of synthetic peptides used for raising antibodies. After preincubation, [ 3 H]prazosin binding was assayed according to the above protocol with a radioligand concentration of 0.5 nmol/L.
Data Analysis
Data from binding and competition experiments were calculated with the Radlig program. 19 In experiments performed with antibodies against ␣ 1 -adrenergic receptor subtype, [ 3 H]prazosin binding in the presence of preabsorbed antibody was considered as total binding. Binding values obtained in the presence of antibodies against ␣ 1A -, ␣ 1B -, and ␣ 1D -adrenergic receptor concentrations causing maximal inhibition of radioligand binding to human peripheral blood lymphocyte (0.5 g/mL) were considered to represent nonspecific retention of radioligand to lymphocyte preparation or to be the result of labeling sites other than ␣ 1 -adrenergic receptors. The difference between total binding and nonspecific radioligand retention was considered as the specific binding defined immunochemically. 
Chemicals
Results
Reverse Transcription-Polymerase Chain Reaction
RT-PCR amplified a 348-bp ␣ 1A -adrenergic receptor fragment, a 689-bp ␣ 1B -adrenergic receptor fragment, and a 540-bp ␣ 1D -adrenergic receptor fragment (Figure 1 , panels labeled A). ␣ 1B -Adrenergic receptor mRNA was expressed with higher abundance than ␣ 1A -and ␣ 1D -adrenergic receptor mRNAs (Figure 1, panels labeled A) . The agarose gel was then blotted onto a nylon filter and hybridized with the nested oligonucleotides to increase the sensitivity of detection (Figure 1, panels labeled B ).
Radioligand Binding Assay
[ 3 H]Prazosin was bound specifically to human peripheral blood lymphocytes. The binding was concentration dependent, with a K d value of 0.65Ϯ0.05 nmol/L (Figure 2A) and B max of 175.3Ϯ20.5 fmol/10 6 cells ( Figure 2B ).
Analysis of data on the pharmacological profile of [ 3 H]prazosin binding to human peripheral blood lymphocytes showed that the most powerful displacers of [ 3 H]prazosin were antagonists of different subtypes of ␣ 1 -adrenergic receptors (spiperoneϾ(Ϫ)-trans-mephendioxanϾ(ϩ)-niguldipineϾ5-methyl-urapidil) or nonselective ␣ 1 -or ␣-adrenergic receptor antagonists (prazosinϾphentolamine) (Table) . The ␣ 2 -adrenergic receptor agonist clonidine, norepinephrine, the ␤-adrenergic receptor antagonist pindolol, and compounds active on dopamine (dopamine) and serotonin receptors (serotonin and methysergide) ( Table) were much less potent than compounds with an ␣-adrenergic receptor profile or were ineffective as displacers of [ 3 H]prazosin binding. Anti-␣ 1A -, anti-␣ 1B -, and anti-␣ 1D -adrenergic receptor immunoglobulins decreased [ 3 H]prazosin binding to human peripheral blood lymphocytes progressively from an immunoglobulin concentration of 0.1 to 0.2 g/mL ( Figure 2C) . The maximal inhibition of [ 3 H]prazosin binding was observed at an immunoglobulin concentration of 0.5 g/mL ( Figure  2C) . No further decrease of binding was noticeable at higher immunoglobulin concentrations ( Figure 2C ). Analysis of inhibition of [ 3 H]prazosin binding by single antibodies against ␣ 1 -adrenergic receptor subtypes or by immunoglobulins in association showed that about 28% of sites labeled by [ 3 H]prazosin corresponded to ␣ 1A -adrenergic receptors, 40% to ␣ 1B -adrenergic receptors, and 18% to ␣ 1D -adrenergic receptors ( Figure 2C ). Immunoglobulins preadsorbed with synthetic peptides used for raising antibodies did not affect [ 3 H]prazosin binding to human peripheral blood lymphocytes ( Figure 2C ).
Discussion
Elevated sympathoadrenal tone and imbalance of ␣and ␤-adrenergic receptor function are important factors in the pathogenesis of essential hypertension. 21 ␣ 1 -Adrenergic receptors are important mediators of the sympathetic neuroeffector system, 12 mediate positive inotropic effects of epinephrine in rat ventricular strips, and participate in vascular smooth muscle tone regulation. [21] [22] [23] ␣-Adrenergic receptor activation contracts isolated blood vessels and increases blood pressure in vivo. [21] [22] [23] On the basis of these observations ␣-adrenergic receptor blockade was introduced for the treatment of hypertension. 18 The development of selective ␣ 1adrenergic receptor antagonists (prazosin and its derivatives) has led to the widespread use of these drugs as antihypertensive agents for many years. 18 The ␣ 1 -adrenergic receptor subtype responsible for vascular contraction may depend on both the vascular bed and the species investigated. 12, 18 The ␣ 1 -adrenergic receptor subtype(s) responsible for blood pressure regulation in the intact individual has been not identified yet. The most probable reasons for the limited amount of information on the topic are the complexity of investigating sympathetic cardiovascular activity in vivo and the difficulty of obtaining samples of human vascular tissue suitable for pharmacological and functional analysis in vitro.
It has been hypothesized that analysis of peripheral blood lymphocyte adrenergic receptor expression may represent a model for studying the cardiovascular adrenergic receptor system. [1] [2] [3] [4] [5] [6] [7] The suitability of techniques so far proposed for demonstrating ␣-adrenergic receptor expression in normal lymphoid cells is still controversial. ␣ 2 -Adrenergic receptors were demonstrated in human peripheral blood lymphocytes using [ 3 H]yohimbine and [ 3 H]clonidine as radioligands. 6, 7 Radioligand binding studies performed with [ 3 H]prazosin were unable to identify ␣ 1 -adrenergic receptors in normal 8 or leukemic human lymphocytes 7 or reported the expression of these receptors in peripheral human natural killer cells. 10 In view of these discrepancies we have reinvestigated the topic using both molecular biology and radioligand binding assay techniques. Currently, truly selective agonists or antagonists for discriminating ␣ 1 -adrenergic receptor subtypes are not available. 18 In view of this, we used antibodies against ␣ 1A -, ␣ 1B -, and ␣ 1D -adrenergic receptor subtypes for investigating the receptor subtypes labeled by [ 3 H]prazosin in blood lymphocytes.
The present study has shown, with the use of different techniques, such as RT followed by nested PCR and radioligand binding assay in association with specific antibodies against ␣ 1 -adrenergic receptor subtypes, that human peripheral blood lymphocytes express the three ␣ 1 -adrenergic receptor subtypes so far identified (␣ 1A , ␣ 1B , and ␣ 1D ). The density of ␣ 1 -adrenergic receptors assayed in the present study is rather high (175.3Ϯ20.5 fmol/10 6 cells). This suggests that human peripheral blood lymphocyte ␣ 1 -adrenergic receptors may have functional relevance. Comparative analysis of the density of ␣ 1 -adrenergic receptors measured in this work with data reported for lymphocyte ␣ 2 -adrenergic receptors 6,7 showed a ratio of ␣ 1 -to ␣ 2adrenergic receptor of approximately 7.9 in human peripheral blood lymphocytes. The role of lymphocyte ␣ 1 -adrenergic receptors has not been clarified yet. It has been suggested that ␣ 1 -adrenergic receptors modulate lymphohematopoiesis. 10 The ␣ 1 -adrenergic receptor antagonist prazosin enhances myelopoiesis and decreases the number of thymocytes and of splenic T and B lymphocytes. 10 Future studies should clarify the possible roles of the different receptor subtypes on lymphocyte function.
The association of [ 3 H]prazosin radioligand binding assay with antibodies raised against the different ␣ 1 -adrenergic receptor subtypes has shown that ␣ 1B receptor is the ␣ 1adrenergic receptor subtype most represented in human peripheral blood lymphocytes and ␣ 1D receptor, the least. These radioligand binding data are consistent with semiquantitative analysis of mRNA levels tested by RT-PCR. Future studies should clarify the relevance of this uneven density of ␣ 1adrenergic receptor. In view of the involvement of ␣ 1 -adrenergic receptors in the regulation of cardiovascular homeostasis, 12 ␣ 1 -adrenergic receptor subtype expression in human peripheral blood lymphocytes may represent a marker of the status of ␣ 1adrenergic receptors in cardiovascular disorders or may be useful for monitoring responses of these receptors to drug treatment. In line with this hypothesis are our preliminary results suggesting a downregulation of lymphocyte ␣ 1adrenergic receptors in patients with essential hypertension.
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